Monte Rosa Therapeutics, Inc. (GLUE)
$
5.26
-0.03 (-0.57%)
Key metrics
Financial statements
Free cash flow per share
0.3710
Market cap
323.5 Million
Price to sales ratio
2.0286
Debt to equity
0.1521
Current ratio
5.6113
Income quality
5.6345
Average inventory
0
ROE
0.0265
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company engaged in the innovative development of small molecule precision medicines that utilize the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The net income ratio is -0.96 reflecting the company's profitability margin. Among its key products is an oral molecular glue degrader aimed at GSPT1, a translational termination factor that plays a significant role in Myc-driven cancers. Additionally, the company is advancing its work on CDK2 for treating ovarian, uterine, and breast cancers, as well as NEK7, which is being developed for inflammatory diseases, including Crohn's disease, neurodegenerative diseases, diabetes, and liver disease. The gross profit stands at $67,501,000.00 highlighting the company's profitability from core operations. Furthermore, Monte Rosa is focused on VAV1, a target protein linked to autoimmune diseases, and BCL11A, relevant in the treatment of hemoglobinopathies. The EBITDA ratio is -0.97 highlighting the company's operational efficiency, while depreciation and amortization expenses of $8,121,000.00 reflect the wear and tear of its assets. The company also incurred an income tax expense of $2,570,000.00 indicating its tax obligations. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. With a market capitalization of $323,541,548.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. The stock is affordable at $5.26 suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 474,360.00 indicating strong liquidity, which may attract a wide range of investors. Belonging to the Healthcare sector, Monte Rosa is driving innovation and growth, serving as an important contributor to advancements in biopharmaceutical solutions. This positioning enhances the company's appeal as it continues to innovate in developing targeted therapies that leverage the body’s own biological processes for treating serious health conditions.
Is Monte Rosa Therapeutics, Inc. (GLUE) a good investment?
Investing in Monte Rosa Therapeutics, Inc. (GLUE) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Monte Rosa Therapeutics, Inc. (GLUE)'s stock forecast?
Analysts predict Monte Rosa Therapeutics, Inc. stock to fluctuate between $3.50 (low) and $12.40 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Monte Rosa Therapeutics, Inc.'s market capitalization?
As of 2025-07-10, Monte Rosa Therapeutics, Inc.'s market cap is $323,541,548, based on 61,509,800 outstanding shares.
How does Monte Rosa Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Monte Rosa Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Monte Rosa Therapeutics, Inc. (GLUE) stock?
To buy Monte Rosa Therapeutics, Inc. (GLUE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GLUE. Place an order (Market, Limit, etc.).
What is the best time to invest in Monte Rosa Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Monte Rosa Therapeutics, Inc. perform in the last earnings report?
Revenue: $75,622,000 | EPS: -$0.98 | Growth: -62.74%.
Where can I find Monte Rosa Therapeutics, Inc.'s investor relations reports?
Visit https://www.monterosatx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Monte Rosa Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Monte Rosa Therapeutics, Inc. stock?
All-time high: $45.56 (2021-09-07) | All-time low: $2.44 (2023-10-25).
What are the key trends affecting Monte Rosa Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries featured on the cover of Science. The research article, “Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition,” details how Monte Rosa's proprietary artificial intelligence (AI) and machine learning (ML) engine has uncovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes.
zacks.com
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year ago.
globenewswire.com
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Cyclin E1 (CCNE1) and CDK2-directed MGD programs for the treatment of CCNE1-driven solid tumors and ER+ breast cancer advancing toward the clinic; IND submission anticipated in 2026 Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2025. “We've made significant progress across our entire portfolio in the development of our only-in-class and first-in-class molecular glue degrader therapeutics, targeting diseases poorly addressed by conventional pharmaceutical approaches,” said Markus Warmuth, M.D.
zacks.com
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ago.
globenewswire.com
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P.
zacks.com
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
globenewswire.com
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D.
globenewswire.com
BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the closing of the Company's previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs, including MRT-6160. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 clinical studies.
globenewswire.com
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended Phase 2 dose determined as 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025 BOSTON, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported an update from its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered and developed by Monte Rosa Therapeutics.
See all news
